Drug intelligence / Profile preview

XLS-103

Development stage: Unknown
Lead developer: Xiangxue Pharmaceutical
Modality: Small Molecules
Administration: Injection

Overview

XLS-103 is an investigational therapeutic being developed by Guangzhou Xiangxue Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. As of 2025, the drug has received Investigational New Drug (IND) approval. It is formulated for administration via injection. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is a component of Xiangxue's oncology pipeline, which focuses on innovative treatments for solid tumors.

Other names: XLS103XLS-103XLS 103

Targets

KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)

Beyond the preview

Go deeper on XLS-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XLS-103.

Explore the full profile